Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Ovarian fibroma/fibrothecoma: retrospective cohort study shows limited value of risk of malignancy index score.

Numanoglu C, Kuru O, Sakinci M, Akbayır O, Ulker V.

Aust N Z J Obstet Gynaecol. 2013 Jun;53(3):287-92. doi: 10.1111/ajo.12090.

PMID:
23611791
2.

MRI features of ovarian fibroma and fibrothecoma with histopathologic correlation.

Shinagare AB, Meylaerts LJ, Laury AR, Mortele KJ.

AJR Am J Roentgenol. 2012 Mar;198(3):W296-303. doi: 10.2214/AJR.11.7221.

PMID:
22358029
3.

Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.

Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, Nustad K.

Br J Obstet Gynaecol. 1996 Aug;103(8):826-31.

PMID:
8760716
4.

The risk of malignancy index in discrimination of adnexal masses.

Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A.

Int J Gynaecol Obstet. 2007 Mar;96(3):186-91.

PMID:
17280665
5.

Magnetic resonance imaging features of ovarian fibroma, fibrothecoma, and thecoma.

Chung BM, Park SB, Lee JB, Park HJ, Kim YS, Oh YJ.

Abdom Imaging. 2015 Jun;40(5):1263-72. doi: 10.1007/s00261-014-0257-z.

PMID:
25273949
6.

Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.

Alanbay I, Akturk E, Coksuer H, Ercan M, Karaşahin E, Dede M, Yenen MC, Ozan H, Baser I.

Gynecol Endocrinol. 2012 Jun;28(6):478-82. doi: 10.3109/09513590.2011.633663.

PMID:
22122561
7.

Imaging in gynecological disease (5): clinical and ultrasound characteristics in fibroma and fibrothecoma of the ovary.

Paladini D, Testa A, Van Holsbeke C, Mancari R, Timmerman D, Valentin L.

Ultrasound Obstet Gynecol. 2009 Aug;34(2):188-95. doi: 10.1002/uog.6394.

8.

External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.

van den Akker PA, Zusterzeel PL, Aalders AL, Snijders MP, Samlal RA, Vollebergh JH, Kluivers KB, Massuger LF.

Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):422-5. doi: 10.1016/j.ejogrb.2011.07.035.

9.

Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women.

Ertas S, Vural F, Vural F, Tufekci EC, Ertas AC, Kose1 G, Aka N.

Asian Pac J Cancer Prev. 2016;17(4):2177-83.

10.

Clinical characteristics and surgical management options for ovarian fibroma/fibrothecoma: a study of 97 cases.

Cho YJ, Lee HS, Kim JM, Joo KY, Kim ML.

Gynecol Obstet Invest. 2013;76(3):182-7. doi: 10.1159/000354555.

PMID:
24051436
11.
12.

Evaluation of the risk malignancy index diagnostic value in patients with adnexal masses.

Terzić M, Dotlić J, Ladjević IL, Atanacković J, Ladjević N.

Vojnosanit Pregl. 2011 Jul;68(7):589-93.

PMID:
21899180
13.

Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.

Leelahakorn S, Tangjitgamol S, Manusirivithaya S, Thongsuksai P, Jaroenchainon P, Jivangkul C.

J Med Assoc Thai. 2005 Oct;88 Suppl 2:S22-30.

PMID:
17718292
14.

Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison.

Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZF, Fang GP.

J Ovarian Res. 2016 Nov 22;9(1):81.

15.

Sonographic discrimination between benign and malignant adnexal masses in premenopause.

Radosa MP, Vorwergk J, Fitzgerald J, Kaehler C, Schneider U, Camara O, Runnebaum IB, Schleußner E.

Ultraschall Med. 2014 Aug;35(4):339-44. doi: 10.1055/s-0033-1335728.

PMID:
23775448
16.

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.

Håkansson F, Høgdall EV, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Høgdall C; DANISH ‘PELVIC MASS’ OVARIAN CANCER STUDY..

Acta Obstet Gynecol Scand. 2012 Apr;91(4):496-502. doi: 10.1111/j.1600-0412.2012.01359.x.

PMID:
22229703
17.

The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.

Moolthiya W, Yuenyao P.

Asian Pac J Cancer Prev. 2009;10(5):865-8.

18.

Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.

Yenen MC, Alanbay I, Aktürk E, Ercan CM, Coksuer H, Karaşahin E, Ozan H, Dede M.

Eur J Gynaecol Oncol. 2012;33(2):168-73.

PMID:
22611957
19.

The risk of malignancy index (RMI) in women with adnexal masses in Wales.

Abdulrahman GO Jr, McKnight L, Lutchman Singh K.

Taiwan J Obstet Gynecol. 2014 Sep;53(3):376-81. doi: 10.1016/j.tjog.2014.05.002.

20.

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L.

J Natl Cancer Inst. 2007 Nov 21;99(22):1706-14.

PMID:
18000221

Supplemental Content

Support Center